Women who skip mammo face higher risk of death
Older adult women who do not undergo regular screening mammography are more likely to die of breast cancer than women who are scanned, according to a long-term study of breast imaging in Massachusetts.
Older adult women who do not undergo regular screening mammography are more likely to die of breast cancer than women who are scanned, according to a long-term study of breast imaging in Massachusetts.
Dr. Blake Cady, professor emeritus of surgery at Harvard, and colleagues reviewed the cases of 6997 women who were diagnosed with invasive breast cancer between 1990 and 1999. All women also underwent follow-up through 2007. Cady confirmed 461 deaths, 116 for regularly screened women and 345 among women who were not regularly screened. Nearly two-thirds (60.9%) of deaths involved women who had never undergone screening while 5% occurred for those with at least one previous mammogram, but not within two years of diagnosis. The study was presented at the 2009 Breast Cancer Symposium in San Francisco.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
